(UroToday.com) The treatment landscape in the first-line therapy of metastatic renal cell carcinoma (mRCC) has rapidly evolved over the past 3 years. In spite of all these changes, more changes are coming. In a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting, Dr. Vano discussed biomarker-driven trials.